吡咯替尼(一种新型不可逆泛ErbB受体酪氨酸激酶抑制剂)在人表皮生长因子受体2阳性转移性乳腺癌患者中的I期研究及生物标志物分析
这项I期研究评估了吡咯替尼在HER2阳性转移性乳腺癌患者中的安全性、耐受性、药代动力学、抗肿瘤活性及预测生物标志物。38例患者入组,最大耐受剂量为400 mg,剂量限制性毒性为3级腹泻。总缓解率为50.0%(18/36),中位无进展生存期为35.4周(95%CI 23.3至40.0周)。
要点
- 最大耐受剂量为400 mg,剂量限制性毒性为3级腹泻(480 mg组2例发生)。
- 总缓解率50.0%(18/36),临床获益率61.1%(22/36),中位无进展生存期35.4周。
- 循环肿瘤DNA中PIK3CA和TP53突变可能预测疗效(P=0.013),而存档肿瘤组织无预测意义(P=0.474)。
核心结论
- 连续每日一次口服吡咯替尼耐受性良好,在HER2阳性转移性乳腺癌患者中显示出有前景的抗肿瘤活性,最大耐受剂量为400 mg,腹泻为剂量限制性毒性,值得进一步开展II期研究评估。
研究设计与样本
- I期研究,纳入38例既往未接受过HER2酪氨酸激酶抑制剂治疗的HER2阳性转移性乳腺癌患者,每日一次口服吡咯替尼,计划剂量递增为80、160、240、320、400和480 mg。
- 第1天和第28天采集定时血样进行药代动力学分析,对循环肿瘤DNA和肿瘤样本基因组DNA进行二代测序。
主要发现
- 剂量限制性毒性为3级腹泻,发生于2例接受480 mg吡咯替尼的患者,最大耐受剂量为400 mg。
- 常见吡咯替尼相关不良事件包括腹泻44.7%(17/38)、恶心13.2%(5/38)、口腔溃疡13.2%(5/38)、乏力10.5%(4/38)和白细胞减少10.5%(4/38),唯一3级不良事件为腹泻。
- 药代动力学分析表明吡咯替尼暴露呈剂量依赖性。
- 总缓解率为50.0%(18/36),临床获益率(完全缓解+部分缓解+疾病稳定≥24周)为61.1%(22/36),中位无进展生存期为35.4周(95%CI 23.3至40.0周)。
- 曲妥珠单抗未经治患者的总缓解率为83.3%(10/12),曲妥珠单抗经治患者为33.3%(8/24)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Patients and Methods Pyrotinib was administered continuously, orally, once per day to patients who did not have prior exposure to tyrosine kinase inhibitors of HER2. Planned dose escalation was 80, 160, 240, 320, 400, and 480 mg. For pharmacokinetic analysis, timed blood samples were collected on day 1 and day 28. Next-generation sequencing was performed on circulating tumor DNA and genomic DNA from tumor samples. Results Thirty-eight patients were enrolled. The dose-limiting toxicity was grade 3 diarrhea, which occurred in two patients administered 480 mg of pyrotinib; thus, the maximum tolerated dose was 400 mg. Common pyrotinib-related adverse events included diarrhea (44.7% [17 of 38]), nausea (13.2% [five of 38]), oral ulceration (13.2% [five of 38]), asthenia (10.5% [four of 38]), and leukopenia (10.5% [four of 38]). The only grade 3 adverse event was diarrhea. Pharmacokinetic analyses indicated that pyrotinib exposure was dose dependent. The overall response rate was 50.0% (18 of 36), and the clinical benefit rate (complete response + partial response + stable disease ≥ 24 weeks) was 61.1% (22 of 36). The median progression-free survival was 35.4 weeks (95% CI, 23.3 to 40.0 weeks). The overall response rate was 83.3% (10 of 12) in trastuzumab-naive patients and 33.3% (eight of 24) in trastuzumab-pretreated patients. Preliminary results suggest that PIK3CA and TP53 mutations in circulating tumor DNA ( P = .013) rather than in archival tumor tissues ( P = .474) may predict the efficacy of pyrotinib. Conclusion Continuous once-per-day pyrotinib was well tolerated and demonstrated promising antitumor activity in HER2-positive patients with metastatic breast cancer. The maximum tolerated dose was established as 400 mg. Diarrhea was the dose-limiting toxicity. The promising antitumor activity and acceptable tolerability of pyrotinib warrant its further evaluation in a phase II study.
引用
- Ma F, Li Q, Chen S, et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2017. PMID: 28498781. doi:10.1200/JCO.2016.69.6179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。